J Retin.  2021 Nov;6(2):99-109. 10.21561/jor.2021.6.2.99.

Clinical Outcomes of Aflibercept Treatment for Treatment-naive Exudative Age-related Macular Degeneration

  • 1Department of Ophthalmology, Gyeongsang National University School of Medicine, Jinju, Korea
  • 2Gyeongsang Institute of Health Science, Gyeongsang National University, Jinju, Korea


To evaluate the 1-year outcomes of the treat-and-extend regimen using intravitreal injection of aflibercept for treatment-naive exudative age-related macular degeneration (AMD) and the clinical results of switching to ranibizumab within the same period.
The change in best-corrected visual acuity (BCVA), central macular thickness (CMT) and number of injections was evaluated in 36 eyes first diagnosed with exudative AMD and treated with the treat-and-extend regimen using intravitreal injection of aflibercept, as well as 16 eyes switched from aflibercept to ranibizumab for improved efficacy within the same period.
Mean BCVA improved significantly from 0.57 ± 0.28 logarithm of the minimum angle of resolution (logMAR) to 0.39 ± 0.29 logMAR at 12 months (p = 0.015) and mean CMT decreased significantly from 406.34 ± 69.18 μm to 269.58 ± 83.15 μm at 12 months in the 36 eyes on the treat-and-extend regimen of aflibercept (p = 0.004). The average number of injections per year was 6.8 ± 0.5. Of the 16 eyes that underwent a change in medication, seven eyes (63.6%) exhibited improvement or maintenance of initial visual acuity; mean CMT decreased significantly from 415.27 ± 73.63 μm prior to drug switch to 289.63 ± 62.78 μm after drug switch in the 11 eyes that received three injections of ranibizumab (p = 0.009).
A treat-and-extend regimen of intravitreal aflibercept injection was effective for exudative AMD in a clinical setting. Switching to ranibizumab for improved efficacy led to anatomical improvement and could help stabilize vision.


Aflibercept; Age-related macular degeneration; Treat-and-extend regimen
Full Text Links
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr